# Therapeutic Proteins Oral Vaccines Market > Therapeutic Proteins And Oral Vaccines Market Research Report By Therapeutic Class (Antibodies, Enzymes, Hormones, Growth factors, Polypeptides), By Vaccine Type (Live attenuated, Inactivated, Toxoid, Subunit, Conjugate), By Disease Indication (Cancer, Cardiovascular diseases, Autoimmune diseases, Infectious diseases, Neurological disorders), By Route of Administration (Intravenous, Subcutaneous, Intramuscular, Oral, Topical) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.63% - **2024:** $ 222.83 Billion - **2025:** $ 242.06 Billion - **2035:** $ 554 Billion - **Key Players:** AbbVie (US), Amgen (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Merck & Co. (US), Novartis (CH), Pfizer (US), Roche (CH), Sanofi (FR), GSK (GB) **Report ID:** MRFR/Pharma/26212-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/therapeutic-proteins-oral-vaccines-market-27899 --- ## Market Summary ## **Therapeutic Proteins And Oral Vaccines Market Overview** As per MRFR analysis, the Therapeutic Proteins And Oral Vaccines Market Size was estimated at 222.83 (USD Billion) in 2024. The Therapeutic Proteins And Oral Vaccines Market Industry is expected to grow from 242.06 (USD Billion) in 2025 to 509.98 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 8.63% during the forecast period (2025 - 2034). **Key Therapeutic Proteins And Oral Vaccines Market Trends Highlighted** The rising prevalence of chronic diseases fuels demand for therapeutic proteins and oral vaccines. Advancements in biotechnology, such as genetic engineering and cell culture technologies, enhance the efficacy and production efficiency of these products.Growing government initiatives and funding support research and development in this field, particularly in developing countries. Additionally, increasing healthcare expenditure and the expansion of healthcare coverage contribute to market growth. The shift towards personalized medicine, where therapies are tailored to individual patient needs, drives the development of targeted therapeutic proteins and oral vaccines. Furthermore, partnerships and collaborations between pharmaceutical companies and research institutions accelerate innovation and bring new products to market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Therapeutic Proteins And Oral Vaccines Market Drivers** Rising Prevalence of Chronic Diseases One of the key drivers of the Therapeutic Proteins And Oral Vaccines Market Industry is the increasing prevalence of several chronic diseases, such as cancer, cardiovascular diseases and autoimmune disorders. As cases of these conditions have been increasing, an increasing need for new treatment and targeted therapy has grown. Due to the desired efficacy and specificity of therapeutic proteins and oral vaccines for chronic diseases of other therapeutic products, the market for the population is growing.There is a growing need for improved targeted and personalized treatment approaches that therapeutic proteins and oral vaccines can offer. In this respect, as the occurrence of chronic diseases will continue to increase in the future, the demand for therapeutic proteins and oral vaccines is projected to be highly viable. Technological Advancements and Innovation The technological advancements in the Therapeutic Proteins And Oral Vaccines Market Industry are causing the evolution of new and more effective treatment options. The application of biotechnological and genetic knowledge has enhanced the development of proteins that are highly specific to their targets, thereby producing highly powerful therapeutic proteins, which include monoclonal antibodies and fusion proteins. The development of these treatments has enabled the fight of previously incurable diseases such as cancer and autoimmune diseases.Besides, the advancement has facilitated the development of vaccines that are oral, innovative and convenient, thereby expanding the market. Government Initiatives and Support Government initiatives and support are crucial factors contributing to the growth of the Therapeutic Proteins And Oral Vaccines Market Industry. Countries all over the world have begun to realize the importance of investing in healthcare and research, which can lead to better health conditions for the general public. This support often comes in the form of funding for research and development and tax incentives for the companies that are involved in the industry.Regulating policies and taxation that are put in place by the government for the companies that are involved in these sectors are also considered a part of government initiatives. Moreover, the government can also heavily focus on running public awareness campaigns to educate people regarding the benefits of therapeutic proteins and oral vaccines, hence leading to an increase in demand for these. **Therapeutic Proteins And Oral Vaccines Market Segment Insights** **Therapeutic Proteins And Oral Vaccines Market Therapeutic Class Insights** The Therapeutic Proteins And Oral Vaccines Market is segmented into various classes based on therapeutic applications. Some of the key therapeutic classes in the market include antibodies, enzymes, hormones, growth factors and polypeptides. Each class has its unique characteristics and applications, contributing to the overall growth of the Therapeutic Proteins And Oral Vaccines Market. Antibodies accounted for the largest therapeutic Proteins And Oral Vaccines Market share in 2023, and this trend is expected to continue during the forecast period.Antibodies are proteins produced by the immune system to neutralize pathogens and toxins. They play a crucial role in treating various diseases, including cancer, autoimmune disorders and infectious diseases. Enzymes are proteins that catalyze chemical reactions in the body. They are used in various therapeutic applications, such as enzyme replacement therapy for genetic disorders and digestive enzyme supplements. The increasing prevalence of chronic diseases, such as diabetes and cancer, is driving the demand for enzyme-based therapies, contributing to the growth of the Therapeutic Proteins And Oral Vaccines Market.Hormones are proteins that regulate various physiological processes in the body. They are used in hormone replacement therapy for conditions such as menopause, growth hormone deficiency, and thyroid disorders. The growing geriatric population and the increasing incidence of hormone-related disorders are expected to fuel the demand for hormone-based therapeutics, propelling the growth of the Therapeutic Proteins And Oral Vaccines Market. Growth factors are proteins that stimulate cell growth and proliferation. They are used in various therapeutic applications, including wound healing, bone regeneration, and tissue engineering.Advances in biotechnology and regenerative medicine are expected to drive the demand for growth factor-based therapies, contributing to the growth of the Therapeutic Proteins And Oral Vaccines Market. Polypeptides are short chains of amino acids that have various therapeutic applications. They are used in antibiotics, hormones, and other therapeutic agents. The increasing demand for targeted therapies and the development of novel polypeptide-based drugs are expected to drive the growth of the Therapeutic Proteins And Oral Vaccines Market. Overall, the Therapeutic Proteins And Oral Vaccines Market is expected to continue growing at a steady pace, driven by the increasing prevalence of chronic diseases, the development of novel therapeutic modalities, and the growing demand for personalized and targeted therapies. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Therapeutic Proteins And Oral Vaccines Market Vaccine Type Insights** The Therapeutic Proteins And Oral Vaccines Market is segmented into five types of vaccines, namely, live attenuated, inactivated, toxoid, subunit, and conjugate. Among these segments, the subunit vaccines segment is expected to hold the largest market share in 2023 and is projected to grow at a CAGR of 8.63% from 2024 to 2034. Subunit vaccines are composed of purified pieces of a pathogen, such as a protein or polysaccharide. Since they do not contain any live or inactivated virus or bacteria, they are safer than live attenuated or inactivated vaccines and are less likely to cause side effects.The live attenuated vaccines segment is the second largest segment in the Therapeutic Proteins And Oral Vaccines Market and is expected to grow at a CAGR of 8.63% from 2024 to 2034. Live attenuated vaccines are made from a weakened form of the pathogen and offer long-lasting immunity. However, they can also cause side effects, such as fever and rash. The inactivated vaccines segment is the third largest segment in the Therapeutic Proteins And Oral Vaccines Market and is expected to grow at a CAGR of 8.63% from 2024 to 2034. Inactivated vaccines are made from a killed form of the pathogen and are less likely to cause side effects than live attenuated vaccines.However, they may not provide long-lasting immunity. The toxoid vaccines segment is the fourth largest segment in the Therapeutic Proteins And Oral Vaccines Market and is expected to grow at a CAGR of 8.63% from 2024 to 2034. Toxoid vaccines are made from a toxin that has been chemically modified to make it harmless. They are used to prevent diseases such as tetanus and diphtheria. The conjugate vaccines segment is the fifth largest segment in the Therapeutic Proteins And Oral Vaccines Market. **Therapeutic Proteins And Oral Vaccines Market Disease Indication Insights** The Disease Indication segment of the Therapeutic Proteins And Oral Vaccines Market is expected to grow significantly in the coming years. Key drivers of this growth include the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, autoimmune diseases, infectious diseases and neurological disorders. The Therapeutic Proteins And Oral Vaccines Market for Cancer is expected to reach a valuation of USD 152.3 billion by 2023, growing at a CAGR of 8.4%. The Cardiovascular diseases segment is also expected to witness significant growth, reaching a valuation of USD 72.6 billion by 2024, growing at a CAGR of 7.9%.The Autoimmune diseases segment is expected to reach a valuation of USD 55.4 billion by 2023, growing at a CAGR of 7.6%. The Infectious diseases segment is expected to reach a valuation of USD 48.3 billion by 2023, growing at a CAGR of 7.2%. The Neurological disorders segment is expected to reach a valuation of USD 39.2 billion by 2034, growing at a CAGR of 6.9%. **Therapeutic Proteins And Oral Vaccines Market Route of Administration Insights** The route of administration segment in the Therapeutic Proteins And Oral Vaccines Market is segmented into intravenous, subcutaneous, intramuscular, oral and topical. Intravenous administration is expected to hold the largest market share in 2023 due to the ease of administration and the ability to deliver drugs directly into the bloodstream. Subcutaneous administration is expected to grow at the highest CAGR during the forecast period due to the increasing use of self-injection devices. The oral route of administration is expected to account for a significant share of the market due to the convenience and ease of administration.The topical route of administration is expected to grow at a moderate CAGR during the forecast period due to the increasing use of topical therapies for the treatment of skin diseases. **Therapeutic Proteins And Oral Vaccines Market Regional Insights** The Therapeutic Proteins And Oral Vaccines Market is segmented into North America, Europe, Asia Pacific, South America and the Middle East and Africa. North America is the largest regional segment, accounting for over 40% of the global market in 2023. Europe is the second-largest region, followed by Asia Pacific. The APAC region is expected to grow at the highest CAGR during the forecast period, driven by factors such as rising disposable income, increasing healthcare expenditure, and the growing prevalence of chronic diseases. The South American and MEA regions are also expected to witness significant growth during the forecast period.The growth of the Therapeutic Proteins And Oral Vaccines Market is attributed to factors such as the rising prevalence of chronic diseases, increasing demand for personalized medicine, and technological advancements in the field of biotechnology. The market is also benefiting from government initiatives and support for the development and production of therapeutic proteins and oral vaccines. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Therapeutic Proteins And Oral Vaccines Market Key Players And Competitive Insights** The major players in the Therapeutic Proteins And Oral Vaccines Market industry are taking various measures to maintain their positions and expand their market share. For example, in March 2023, Pfizer Inc. acquired Arena Pharmaceuticals, which is a clinical-stage biopharmaceutical company, in order to bolster its immunology and inflammation research and development. Moreover, in June 2023, Gilead Sciences Inc. reached an agreement with Arcus Biosciences, Inc. to jointly discover, develop and commercialize cancer-related novel immunotherapies. These measures are projected to foster growth in the Therapeutic Proteins And Oral Vaccines Market industry. One of the leading players in the Therapeutic Proteins And Oral Vaccines Market is Pfizer Inc. The company, which is headquartered in New York City, is a research-based global Biopharmaceutical company. It develops and manufactures vaccines and other medicines. Pfizer boasts a number of promising therapeutic proteins and oral vaccines in its pipeline. For instance, it will soon start mass production of Comirnaty, which is an mRNA type vaccine for COVID-19. Its leading position is supported by Pfizer’s strong R&D capabilities and worldwide presence. The company has formed a range of agreements with biotech companies in order to promote the arrival of new drugs. Therefore, one of the main competitors is Moderna, Inc., which is a biotechnology company based in Cambridge, Massachusetts. The company focuses on existing mRNA-based therapeutics and vaccines. Its mRNA COVID-19 vaccine Spikevax has been widely used worldwide. Furthermore, it is currently developing other therapeutics for a number of diseases, such as cancer, cardiovascular diseases, rare diseases and others. Based on the innovative technology platform and promising pipeline, Moderna, Inc. is a significant competitor in the Therapeutic Proteins And Oral Vaccines Market. **Key Companies in the Therapeutic Proteins And Oral Vaccines Market Include** **Therapeutic Proteins And Oral Vaccines Market Industry Developments** The Therapeutic Proteins And Oral Vaccines Market is projected to reach USD 509.98 billion by 2034, exhibiting a CAGR of 8.63% during the forecast period (2025-2034). The market growth is attributed to the rising prevalence of chronic diseases, increasing demand for personalized medicine, and technological advancements in protein engineering and vaccine development. Key recent developments include the approval of novel therapeutic proteins such as Hemlibra and Evrysdi and the ongoing development of mRNA-based oral vaccines for infectious diseases. Major players in the market include AbbVie, Amgen, and Pfizer, who are investing in research and development to expand their product portfolios and address unmet medical needs. **Therapeutic Proteins And Oral Vaccines Market Segmentation Insights** ** ** ** ** ** ** ** ** ## Market Drivers ### Regulatory Support for Biologics Regulatory frameworks are increasingly supportive of biologics, which is a crucial factor for the Therapeutic Proteins And Oral Vaccines Market. Agencies are streamlining approval processes for therapeutic proteins and oral vaccines, thereby facilitating quicker access to the market. Recent initiatives have been introduced to expedite the review of biologics, particularly those addressing unmet medical needs. This regulatory environment encourages pharmaceutical companies to invest in the development of innovative therapies. As a result, the Therapeutic Proteins And Oral Vaccines Market is likely to experience accelerated growth, with a broader range of products becoming available to healthcare providers and patients. ### Rising Prevalence of Chronic Diseases The increasing incidence of chronic diseases such as diabetes, cancer, and autoimmune disorders is driving the Therapeutic Proteins And Oral Vaccines Market. As these conditions become more prevalent, there is a heightened demand for innovative therapeutic solutions. Therapeutic proteins, including monoclonal antibodies and recombinant proteins, are gaining traction due to their targeted action and efficacy. According to recent estimates, the therapeutic proteins market is projected to reach approximately USD 300 billion by 2025, reflecting a compound annual growth rate of around 8%. This growth is indicative of the urgent need for effective treatments, thereby propelling the Therapeutic Proteins And Oral Vaccines Market forward. ### Increased Focus on Preventive Healthcare The shift towards preventive healthcare is reshaping the Therapeutic Proteins And Oral Vaccines Market. As healthcare systems prioritize prevention over treatment, there is a growing emphasis on vaccines and therapeutic proteins that can preemptively address health issues. This trend is evident in the rising demand for oral vaccines, which offer ease of administration and improved patient compliance. Market analysts project that the oral vaccine segment could witness a growth rate of over 10% annually through 2025. This focus on prevention not only enhances public health outcomes but also drives innovation within the Therapeutic Proteins And Oral Vaccines Market. ### Technological Innovations in Drug Development Technological advancements in drug development are significantly influencing the Therapeutic Proteins And Oral Vaccines Market. Innovations such as CRISPR gene editing, high-throughput screening, and artificial intelligence are streamlining the discovery and production of therapeutic proteins. These technologies enhance the efficiency of clinical trials and reduce time-to-market for new therapies. For instance, the integration of AI in drug design has shown potential to decrease development costs by up to 30%. As a result, the market is witnessing an influx of novel therapeutic proteins and oral vaccines, catering to diverse therapeutic areas and expanding the overall market landscape. ### Growing Investment in Biopharmaceutical Research The surge in investment directed towards biopharmaceutical research is a pivotal driver for the Therapeutic Proteins And Oral Vaccines Market. Governments and private entities are increasingly funding research initiatives aimed at developing advanced therapeutic proteins and oral vaccines. In 2025, it is anticipated that global investment in biopharmaceutical R&D will exceed USD 200 billion, reflecting a robust commitment to innovation. This financial backing not only accelerates the development of new therapies but also fosters collaboration among research institutions, thereby enhancing the overall efficacy and safety of therapeutic proteins. Such investments are likely to yield a diverse array of products in the Therapeutic Proteins And Oral Vaccines Market. ## Future Outlook The Therapeutic Proteins and Oral Vaccines Market is projected to grow at an 8.63% CAGR from 2025 to 2035, driven by technological advancements and increasing healthcare demands. **New opportunities:** - Development of personalized therapeutic protein formulations - Expansion of oral vaccine delivery systems in emerging markets - Strategic partnerships for biomanufacturing capabilities enhancement By 2035, the market is expected to achieve robust growth, positioning itself as a leader in innovative healthcare solutions. ## Segment Insights ### By Therapeutic Class: Antibodies (Largest) vs. Enzymes (Fastest-Growing) The Therapeutic Proteins and Oral Vaccines Market showcases distinct segments including Antibodies, Enzymes, Hormones, Growth Factors, and Polypeptides. [Antibodies](https://www.marketresearchfuture.com/reports/antibodies-market-20684)dominate this market, driven by their wide applications in treating diseases such as cancer and autoimmune disorders. Enzymes, while a smaller segment as compared to antibodies, exhibit significant growth potential owing to advancements in enzyme technology and increased research focus on enzyme-based therapies. Antibodies (Dominant) vs. Enzymes (Emerging) Antibodies represent the largest segment in the Therapeutic Proteins market, characterized by their efficacy in targeting specific pathogens and disease-related mechanisms. Their robust pipeline and ongoing clinical trials reinforce their dominance. Conversely, Enzymes are emerging as a transformative therapeutic class, leveraging innovations in biocatalysis and personalized medicine. This segment's growth is fueled by the rising demand for enzyme replacement therapies and growing recognition of their potential in treating metabolic disorders. Both segments are integral to the market's landscape, yet they function with distinct mechanisms and applications that cater to varied therapeutic needs. ### By Vaccine Type: Live Attenuated (Largest) vs. Inactivated (Fastest-Growing) The Therapeutic Proteins and Oral Vaccines Market displays a diverse landscape of vaccine types, with live attenuated vaccines holding the largest share. This segment remains a preferred choice in vaccination programs due to their efficacy and robust immune response. Inactivated vaccines, while traditionally used, are witnessing increased interest, marking them as the fastest-growing segment, driven by advancements in technology and safety profiles. Conjugate and subunit vaccines also hold substantial presence, catering to specific diseases and patient needs, but their market share remains smaller compared to live attenuated and inactivated types. Growth trends in this segment indicate a shift towards new formulations and delivery mechanisms. Factors driving the growth of inactivated vaccines include their safety features and extended stability, appealing to a larger patient demographic. Ongoing research and development efforts aim to enhance the efficacy of subunit and toxoid vaccines, broadening their application scope. Increasing incidences of infectious diseases globally further amplify the need for diverse vaccine solutions, propelling both live attenuated and inactivated vaccines to the forefront of therapeutic innovations. Live Attenuated (Dominant) vs. Inactivated (Emerging) The live attenuated vaccine segment is characterized by its ability to stimulate strong immune responses, making it a dominant player in the therapeutic proteins and oral vaccines market. These vaccines contain weakened forms of the virus or bacteria they protect against, allowing for effective immunity development. They have been widely adopted for various diseases due to their efficacy and long-term immunity benefits. On the other hand, inactivated vaccines are emerging as a significant contender in the market. These vaccines use killed pathogens, which enhance their safety profile and stability, making them increasingly popular among healthcare providers and patients. As immunization strategies evolve, both segments are expected to adapt, ensuring they meet changing health demands. ### By Disease Indication: Cancer (Largest) vs. Infectious diseases (Fastest-Growing) In the Therapeutic Proteins and Oral Vaccines market, cancer remains the largest segment, capturing a significant portion of the market share. This is primarily due to the ongoing demand for innovative therapies and increased funding towards research and development for cancer treatments. Conversely, infectious diseases are emerging as the fastest-growing segment, driven by the heightened focus on vaccine development in response to global health crises. The growth in the infectious diseases segment is fostered by advancements in vaccine technologies and a global push for immunization. The COVID-19 pandemic has notably accelerated the development and approval processes for vaccines, leading to an upsurge in interest and investment in this area. As a result, more companies are exploring protein-based therapies to combat various infectious agents, thereby fueling market expansion in this segment. Cancer (Dominant) vs. Autoimmune diseases (Emerging) The cancer segment in the Therapeutic Proteins and Oral Vaccines Market is characterized by its extensive portfolio of therapies, including monoclonal antibodies and engineered proteins, which have consistently shown efficacy in treating various cancer types. This dominance is supported by substantial R&D investments and a strong pipeline of innovative treatments. In contrast, autoimmune diseases represent an emerging segment that is gaining traction. This growth is spurred by improved diagnostics and a deeper understanding of autoimmune conditions, leading to the development of targeted therapies designed to modulate immune responses. The increasing prevalence of autoimmune disorders and a rising patient population are also factors driving interest and investment in this segment, positioning it for significant future growth. ### By Route of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing) Within the Therapeutic Proteins and Oral Vaccines Market, the distribution of market share across different routes of administration reveals a significant preference for intravenous methods, which currently holds the largest share due to its efficacy in acute therapies and rapid onset of action. Subcutaneous administration, while smaller in share compared to intravenous, exhibits robust growth as it provides greater convenience, leading to an increase in patient compliance and preference, especially in chronic conditions. Intravenous (Dominant) vs. Subcutaneous (Emerging) Intravenous administration remains the dominant route in the Therapeutic Proteins and Oral Vaccines Market due to its ability to deliver high doses directly into the bloodstream, making it ideal for inpatient treatments and acute care. This method facilitates immediate therapeutic effects and is crucial for biologics that require strict control over drug concentrations. In contrast, the subcutaneous route is emerging as a preferred alternative, offering ease of self-administration and less invasive procedures. Its growth is propelled by the rise of self-injectable biologics and vaccines that can be administered for chronic conditions in outpatient settings, highlighting a shift towards more patient-centered therapies. ## Regional Market Share Analysis ### North America : Market Leader in Innovation North America is the largest market for therapeutic proteins and oral vaccines, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, significant R&D investments, and a strong regulatory framework that encourages innovation. The increasing prevalence of chronic diseases and the demand for personalized medicine are key growth drivers, alongside supportive government policies that facilitate drug approvals and market access. The United States is the primary contributor, with major players like AbbVie, Amgen, and Johnson & Johnson leading the market. The competitive landscape is characterized by continuous innovation and strategic partnerships among pharmaceutical companies. Canada also plays a significant role, focusing on biotechnology advancements and regulatory harmonization with the U.S., further enhancing market dynamics. ### Europe : Regulatory Framework and Growth Europe is the second-largest market for therapeutic proteins and oral vaccines, accounting for approximately 30% of the global market share. The region's growth is driven by increasing healthcare expenditure, a rising aging population, and a strong emphasis on research and development. Regulatory bodies like the European Medicines Agency (EMA) play a crucial role in ensuring the safety and efficacy of new therapies, fostering a conducive environment for market expansion. Leading countries include Germany, France, and the UK, which host several key players such as Sanofi and GSK. The competitive landscape is marked by collaborations between pharmaceutical companies and research institutions, enhancing innovation. The European market is also witnessing a surge in biosimilars, driven by regulatory incentives and cost-containment strategies, further shaping the therapeutic landscape. ### Asia-Pacific : Rapid Growth and Potential Asia-Pacific is rapidly emerging as a significant player in the therapeutic proteins and oral vaccines market, holding about 20% of the global market share. The region's growth is fueled by increasing healthcare investments, a large patient population, and rising awareness of advanced therapies. Countries like China and India are leading this growth, supported by government initiatives aimed at enhancing healthcare access and affordability, alongside favorable regulatory environments that encourage innovation. China is the largest market in the region, with a growing number of domestic companies entering the therapeutic proteins space. India follows closely, focusing on vaccine production and biotechnology advancements. The competitive landscape is characterized by a mix of multinational corporations and local firms, driving innovation and expanding market reach. The region's potential is further amplified by increasing collaborations between public and private sectors, enhancing research capabilities. ### Middle East and Africa : Emerging Market Dynamics The Middle East and Africa (MEA) region is witnessing gradual growth in the therapeutic proteins and oral vaccines market, accounting for approximately 5% of the global market share. Key growth drivers include increasing healthcare investments, rising disease prevalence, and government initiatives aimed at improving healthcare infrastructure. Countries like South Africa and the UAE are leading the market, with a focus on enhancing access to innovative therapies and vaccines, supported by regulatory reforms that facilitate market entry. South Africa is the largest market in the region, with a growing emphasis on biotechnology and pharmaceutical manufacturing. The competitive landscape is evolving, with both local and international players striving to capture market share. The presence of key players is increasing, and partnerships between governments and private sectors are fostering innovation and improving healthcare delivery across the region. ## Competitive Benchmarking The major players in the Therapeutic Proteins And Oral Vaccines Market industry are taking various measures to maintain their positions and expand their market share. For example, in March 2023, Pfizer Inc. acquired Arena Pharmaceuticals, which is a clinical-stage biopharmaceutical company, in order to bolster its immunology and inflammation research and development. Moreover, in June 2023, Gilead Sciences Inc. reached an agreement with Arcus Biosciences, Inc. to jointly discover, develop and commercialize cancer-related novel immunotherapies. These measures are projected to foster growth in the Therapeutic Proteins And Oral Vaccines Market industry. One of the leading players in the Therapeutic Proteins And Oral Vaccines Market is Pfizer Inc. The company, which is headquartered in New York City, is a research-based global Biopharmaceutical company. It develops and manufactures vaccines and other medicines. Pfizer boasts a number of promising therapeutic proteins and oral vaccines in its pipeline. For instance, it will soon start mass production of Comirnaty, which is an mRNA type vaccine for COVID-19. Its leading position is supported by Pfizer’s strong R&D capabilities and worldwide presence. The company has formed a range of agreements with biotech companies in order to promote the arrival of new drugs. Therefore, one of the main competitors is Moderna, Inc., which is a biotechnology company based in Cambridge, Massachusetts. The company focuses on existing mRNA-based therapeutics and vaccines. Its mRNA COVID-19 vaccine Spikevax has been widely used worldwide. Furthermore, it is currently developing other therapeutics for a number of diseases, such as cancer, cardiovascular diseases, rare diseases and others. Based on the innovative technology platform and promising pipeline, Moderna, Inc. is a significant competitor in the Therapeutic Proteins And Oral Vaccines Market. ## Recent News & Developments The Therapeutic Proteins And Oral Vaccines Market is projected to reach USD 509.98 billion by 2034, exhibiting a CAGR of 8.63% during the forecast period (2025-2034). The market growth is attributed to the rising prevalence of chronic diseases, increasing demand for personalized medicine, and technological advancements in protein engineering and vaccine development. Key recent developments include the approval of novel therapeutic proteins such as Hemlibra and Evrysdi and the ongoing development of mRNA-based oral vaccines for infectious diseases. Major players in the market include AbbVie, Amgen, and Pfizer, who are investing in research and development to expand their product portfolios and address unmet medical needs. ## Report Scope | MARKET SIZE 2024 | 222.83(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 242.06(USD Billion) | | MARKET SIZE 2035 | 554.0(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.63% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | AbbVie (US), Amgen (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Merck & Co. (US), Novartis (CH), Pfizer (US), Roche (CH), Sanofi (FR), GSK (GB) | | Segments Covered | Therapeutic Class, Vaccine Type, Disease Indication, Route of Administration, Regional | | Key Market Opportunities | Advancements in oral delivery systems enhance accessibility and efficacy in the Therapeutic Proteins And Oral Vaccines Market. | | Key Market Dynamics | Rising demand for innovative therapeutic proteins and oral vaccines drives competitive dynamics and regulatory adaptations in the market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Therapeutic Proteins and Oral Vaccines Market?** A: The market valuation was 222.83 USD Billion in 2024. **Q: What is the projected market size for the Therapeutic Proteins and Oral Vaccines Market by 2035?** A: The projected valuation for 2035 is 554.0 USD Billion. **Q: What is the expected CAGR for the Therapeutic Proteins and Oral Vaccines Market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 8.63%. **Q: Which therapeutic class segment holds the highest market value in the Therapeutic Proteins sector?** A: The Antibodies segment holds the highest market value, with a range from 66.85 to 165.0 USD Billion. **Q: What are the key players in the Therapeutic Proteins and Oral Vaccines Market?** A: Key players include AbbVie, Amgen, Bristol-Myers Squibb, Johnson & Johnson, and Merck & Co. **Q: Which vaccine type is projected to have the highest market value by 2035?** A: The Subunit vaccine type is projected to reach a market value between 60.0 and 130.0 USD Billion. **Q: What disease indication segment is expected to show significant growth in the Therapeutic Proteins and Oral Vaccines Market?** A: The Infectious diseases segment is expected to grow significantly, with a projected range of 60.0 to 150.0 USD Billion. **Q: How does the Oral route of administration compare to other routes in terms of market value?** A: The Oral route is projected to have the highest market value, ranging from 80.0 to 200.0 USD Billion. **Q: What is the market value range for the Enzymes segment in the Therapeutic Proteins category?** A: The Enzymes segment has a market value range from 33.42 to 83.0 USD Billion. **Q: Which company is likely to lead the market in terms of innovation in therapeutic proteins?** A: Companies like Pfizer and Roche are likely to lead in innovation within the therapeutic proteins sector. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/therapeutic-proteins-oral-vaccines-market-27899*